Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Published Time:
2021-03-08 18:01
Source:
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
Founded in 2010, Jiangsu Vcare specializes in end-to-end R&D, services, and innovation across the chemical drug industry chain. Headquartered in Nanjing Biotech and Pharmaceutical Valley, the company employs 280 staff, with over 50% of its R&D team holding master’s or doctoral degrees. It operates a 21,000 sqm high-end drug R&D center equipped with fully functional synthesis, analysis, formulation, cell, and enzyme activity testing laboratories. Its experienced teams in medicinal chemistry, CMC, and clinical development operate under internationally advanced management models, providing comprehensive R&D capabilities spanning "Chemistry + Pharmacy + Medicine".
Focusing on unmet clinical needs in cardiovascular, oncology, and endocrine diseases, Jiangsu Vcare has developed multiple competitive innovative products through independent R&D and collaborative innovation. Its flagship drug Vicagrel—which has completed Phase II trials—was recognized as "one of the most commercially promising projects in its field." The second-generation NTRK inhibitor has entered Phase I, while a highly selective JAK1 inhibitor is nearing IND submission. The pipeline includes multiple first-in-class (FIC) and best-in-class (BIC) preclinical candidates.
In recent years, Jiangsu Vcare has steadily advanced its innovative drug programs while achieving rapid growth in contract services. With investor support, the company aims to accelerate clinical research and deliver more high-quality therapeutics to global patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely appreciate our investors’ recognition of Jiangsu Vcare and their trust in our team. We are in an exhilarating era of innovation, where developing novel drugs to address clinical needs remains our unwavering mission. Simultaneously, in this service-driven economy, we are committed to providing one-stop, full-process drug R&D services that create value for clients. Moving forward, we will continue to prioritize independent innovation and open collaboration to unlock limitless potential."
Next Page
Next Page
Related News
28
2025
/
11
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.
View Details
11
2025
/
11
Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.
View Details
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn